🎉 M&A multiples are live!
Check it out!

Zhejiang Ausun Valuation Multiples

Discover revenue and EBITDA valuation multiples for Zhejiang Ausun and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

Zhejiang Ausun Overview

About Zhejiang Ausun

Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.


Founded

2010

HQ

China
Employees

n/a

Website

ausunpharm.com

Financials

LTM Revenue $121M

LTM EBITDA $52.2M

EV

$1.1B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Zhejiang Ausun Financials

As of December 2025, Zhejiang Ausun reported last 12-month revenue of $121M and EBITDA of $52.2M.

In the same period, Zhejiang Ausun generated $64.7M in LTM gross profit and $31.7M in net income.

See Zhejiang Ausun valuation multiples based on analyst estimates

Zhejiang Ausun P&L

In the most recent fiscal year, Zhejiang Ausun reported revenue of $114M and EBITDA of $44.5M.

Zhejiang Ausun expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Zhejiang Ausun valuation multiples based on analyst estimates
LTM NTM Last FY FY 2026 FY 2027 FY 2028
Revenue $121M XXX $114M XXX XXX XXX
Gross Profit $64.7M XXX $61.6M XXX XXX XXX
Gross Margin 53% XXX 54% XXX XXX XXX
EBITDA $52.2M XXX $44.5M XXX XXX XXX
EBITDA Margin 43% XXX 39% XXX XXX XXX
EBIT $36.4M XXX $29.4M XXX XXX XXX
EBIT Margin 30% XXX 26% XXX XXX XXX
Net Profit $31.7M XXX $29.6M XXX XXX XXX
Net Margin 26% XXX 26% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Zhejiang Ausun Stock Performance

Zhejiang Ausun has current market cap of CNY 8.3B (or $1.2B), and EV of CNY 7.6B (or $1.1B).

Market Cap Evolution

Zhejiang Ausun Stock Data

As of January 16, 2026, Zhejiang Ausun's stock price is CNY 10 (or $1).

See Zhejiang Ausun trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.1B $1.2B XXX XXX XXX XXX $0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Zhejiang Ausun Valuation Multiples

Zhejiang Ausun's trades at 8.9x EV/Revenue multiple, and 20.7x EV/EBITDA.

See valuation multiples for Zhejiang Ausun and 15K+ public comps

Zhejiang Ausun Financial Valuation Multiples

As of January 16, 2026, Zhejiang Ausun has market cap of $1.2B and EV of $1.1B.

Equity research analysts estimate Zhejiang Ausun's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Zhejiang Ausun has a P/E ratio of 37.6x.

LTM NTM Last FY FY 2026 FY 2027 FY 2028
Market cap (current) $1.2B XXX $1.2B XXX XXX XXX
EV (current) $1.1B XXX $1.1B XXX XXX XXX
EV/Revenue 8.9x XXX 8.9x XXX XXX XXX
EV/EBITDA 20.7x XXX 20.7x XXX XXX XXX
EV/EBIT 29.7x XXX 29.7x XXX XXX XXX
EV/Gross Profit 16.7x XXX n/a XXX XXX XXX
P/E 37.6x XXX 37.6x XXX XXX XXX
EV/FCF n/a XXX 113.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Zhejiang Ausun Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Zhejiang Ausun Margins & Growth Rates

Zhejiang Ausun's last 12 month revenue growth is 15%

Zhejiang Ausun's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Zhejiang Ausun's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Zhejiang Ausun's rule of X is 81% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Zhejiang Ausun and other 15K+ public comps

Zhejiang Ausun Operational Valuation Multiples

LTM NTM Last FY FY 2026 FY 2027 FY 2028
Revenue Growth 15% XXX 18% XXX XXX XXX
EBITDA Margin 43% XXX 43% XXX XXX XXX
EBITDA Growth 22% XXX 4% XXX XXX XXX
Rule of 40 57% XXX 58% XXX XXX XXX
Bessemer Rule of X XXX XXX 81% XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX n/a XXX XXX XXX
S&M Expenses to Revenue XXX XXX 1% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 13% XXX XXX XXX
Opex to Revenue XXX XXX 28% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Zhejiang Ausun Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Zhejiang Ausun M&A and Investment Activity

Zhejiang Ausun acquired  XXX companies to date.

Last acquisition by Zhejiang Ausun was  XXXXXXXX, XXXXX XXXXX XXXXXX . Zhejiang Ausun acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Zhejiang Ausun

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About Zhejiang Ausun

When was Zhejiang Ausun founded? Zhejiang Ausun was founded in 2010.
Where is Zhejiang Ausun headquartered? Zhejiang Ausun is headquartered in China.
Is Zhejiang Ausun publicy listed? Yes, Zhejiang Ausun is a public company listed on SHG.
What is the stock symbol of Zhejiang Ausun? Zhejiang Ausun trades under 603229 ticker.
When did Zhejiang Ausun go public? Zhejiang Ausun went public in 2017.
Who are competitors of Zhejiang Ausun? Similar companies to Zhejiang Ausun include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Zhejiang Ausun? Zhejiang Ausun's current market cap is $1.2B
What is the current revenue of Zhejiang Ausun? Zhejiang Ausun's last 12 months revenue is $121M.
What is the current revenue growth of Zhejiang Ausun? Zhejiang Ausun revenue growth (NTM/LTM) is 15%.
What is the current EV/Revenue multiple of Zhejiang Ausun? Current revenue multiple of Zhejiang Ausun is 8.9x.
Is Zhejiang Ausun profitable? Yes, Zhejiang Ausun is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Zhejiang Ausun? Zhejiang Ausun's last 12 months EBITDA is $52.2M.
What is Zhejiang Ausun's EBITDA margin? Zhejiang Ausun's last 12 months EBITDA margin is 43%.
What is the current EV/EBITDA multiple of Zhejiang Ausun? Current EBITDA multiple of Zhejiang Ausun is 20.7x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.